Precigen begins clinical trial for HPV-positive tumors

By The Science Advisory Board staff writers

August 17, 2020 -- Precigen has dosed the first patients with Prgn-2009, an off-the-shelf investigational immunotherapy candidate, in a phase I/II clinical trial for the treatment of cancers associated with human papillomavirus (HPV).

The immunotherapy utilizes the company's UltraVector and AdenoVerse platforms targeting HPV solid tumors. The therapy uses gorilla adenovectors that have large payload capacities and the potential for repeat administration due to very low to no seroprevalence in the human population.

The phase I clinical study will use a 3+3 dose escalation to evaluate the safety of the drug as a monotherapy to determine dosage for the phase II study, followed by safety evaluation in combination with bintrafusp alfa (M7824), an investigational bifunctional fusion protein in patients with recurrent or metastatic HPV-associated cancers. The phase II study will evaluate Prgn-2009 as a monotherapy or in combination with bintrafusp alpha as a neoadjuvant or induction therapy in patients with stage II/III HPV16-positive oropharyngeal cancer.

The investigational immunotherapy is being developed in collaboration with the Center for Cancer Research and the U.S. National Cancer Institute.

Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...
Precigen touts heart failure multigenic therapy results
Precigen is highlighting clinical results from a phase I trial conducted by its subsidiary Precigen Triple-Gene that show that its multigenic investigational...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter